Cure My Disease

Don't miss your cure!

 Log in / Sign up

New combo shows promise for tough bile duct cancer in early trial

NCT ID NCT07530445

Recruiting now Disease control Sponsor: Sun Yat-sen University Source: ClinicalTrials.gov ↗

First seen Apr 17, 2026 · Last updated Jun 13, 2026 · Updated 11 times

Summary

This study tests a new combination of drugs (iparomlimab, tuvonralimab, chemotherapy, and lenvatinib) as a second-line treatment for people with advanced bile duct cancer that has worsened after first-line therapy. The goal is to see if this approach can help control the cancer and improve survival. About 40 participants will be enrolled at a single center in China.

Disclaimer Read more

This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for SECOND-LINE THERAPY FOR UNRESECTABLE OR METASTATIC BILIARY TRACT CANCER are added.

Our safety recommendation!

By submitting, you agree to our Terms of use

Contacts and locations

Study contacts

  • Contact

    Phone: •••-•••-•••• Email: •••••@•••••

Locations

  • Zhiqiang Wang, guangzhou, Other (Non U.S.) 510000 Recruiting

    RECRUITING

    Guangzhou, China

    Contact Phone: •••-•••-•••• Email: •••••@•••••

Conditions

Explore the condition pages connected to this study.

SECOND-LINE THERAPY FOR UNRESECTABLE OR METASTATIC BILIARY TRACT CANCER SECOND-LINE THERAPY FOR UNRESECTABLE OR METASTATIC BILIARY TRACT CANCER

Conditions inferred from the trial description

These were inferred from the trial's summary, not listed by the trial registrant.

UNRESECTABLE OR METASTATIC BILIARY TRACT CANCER